In the News
ICON experts frequently author or contribute to industry trade press.
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category.
-
Considerations for vaccine efficacy trials targeting emerging infectious diseases
Following the COVID-19 pandemic, Shelley McLendon outlines what lessons must be learned to prevent future other emerging infectious diseases developing on a similar scale.
This article is taken from European Biopharmaceutical Review October 2022, pages 16-18. Samedan Ltd
-
Elite stock: ICON sails through trials with top manager
CFO Brendan Brennan outlines what will drive growth at ICON in his interview with Citywire.
-
Supporting reimbursement decisions with data from external control arms
Data is at the heart of every decision made by CROs, and so can have significant legal and financial implications. In this article ICON experts weigh in on maximising the efficacy of data and ensuring the scientific rigour HTAs expect.
This article is taken from European Pharmaceutical Contractor, August 2022, pages 52-55. Samedan Ltd
-
Pharmacovigilance outsourcing: Ensuring a positive experience
Karen Johnstone and Sabine Richter discuss current outsourcing practices and tips for selecting a service provider to ensure a successful relationship.
-
Longitudinal qualitative research - Capturing the patient voice; enhancing patient centricity
Outcomes researchers Alexia Marrel and Sally Lanar share insights on longitudinal qualitative research - what it is, when and how it can be used and the key factors for success when using this type of research.
-
Nominations now open for ‘Company of the Year’ Award 2022
This article features commentary from CEO Steve Cutler about ICON being awarded 2021 Company of the Year.
-
-
How real world evidence is impacting rare disease drug development
Will Maier, VP of Rare Diseases, shares how a more patient-focused approach to trials is leading to alternatives for randomisation.
-
The cross-over of statistical thinking and practices: A pandemic catalyst
This article focuses on what others could learn from good statistical practices in drug development and considers areas where drug development could benefit from some fresh thinking
-
Improving early phase oncology clinical trial design: A case study
Tim Clark, VP Drug Development Solutions and Alan Phillips, Sr. Director Biostatistics present a case study on the first in human Bayesian Optimal Interval design.
